Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 13 957 / https://doi.org/10.3332/ecancer.2019.957

Clinical Study

Early toxicity and treatment outcomes of extended field-intensity modulated radiotherapy for cervical cancer patients with para-aortic nodal metastasis

Objective: Extended-field radiotherapy (EFRT) with concurrent chemotherapy represents standard treatment in cervical cancer patients with para-aortic lymph nodal (PALN) metastasis. While EFRT with Intensity Modulated RT (IMRT) has been demonstrated to reduce toxicities, the dose thresholds for minimizing acute toxicity is not clear. The present study was undertaken to report the early toxicity with extended-field intensity-modulated radiotherapy (EF-IMRT) for carcinoma of the cervix in our cohort of patients and determine dose-volume parameters that predict ≥grade II haematological toxicity and diarrhoea.

Methodology: This was a retrospective study of consecutive cervical cancer patients with PALN metastasis treated with EF-IMRT. Patients received rotational IMRT /- neoadjuvant chemotherapy (NACT) and/or concurrent chemotherapy (45–50 Gy/25#/5 weeks) followed by high-dose rate brachytherapy. Acute haematological and gastrointestinal toxicity (diarrhoea and vomiting) was correlated with doses received by bowel and marrow. Receiver operator characteristics curves were used for deriving thresholds that predict for increased toxicity and tested on univariate and multivariate analysis. Finally, disease free and overall survival (DFS and OS) was calculated.

Results: A total of 43 patients were included. One-fourth of the patients (11/43) received NACT and 88% received concurrent chemotherapy. Within the upfront EF-IMRT cohort, 22.6% and 9.7% patients developed grade ≥III haematological (HT) and gastrointestinal (GI) toxicity respectively, with an increase in HT (≥ grade III HT =67%) in patients receiving NACT (p = 0.007). In the entire cohort bone marrow Volume receiving 10 Gy (V10>) 90% correlated with an increase in ≥ grade III HT (p = 0.05). No dose volume thresholds could be validated for GI toxicity. The OS and DFS at 2 years was 56% and 54%, respectively.

Conclusion: EF-IMRT is a feasible option for cervical cancer patients with PALN involvement and is associated with acceptable grade III toxicity. Future studies need to focus on minimizing HT toxicity.

Keywords: cervical cancer, PALN, EFRT, IMRT, toxicity

Loading Article Metrics ... Please wait

Related articles

Research: Awareness of human papilloma virus and cervical cancer prevention among Cypriot female healthcare workers

Abstract | Full Article | PDF Published: 20 Nov 2019 / https://doi.org/10.3332/ecancer.2019.978

Case Report: Case report of a 65-year-old man with biatrial metastatic localisation from poorly differentiated cutaneous squamous cell carcinoma

Abstract | Full Article | PDF Published: 19 Nov 2019 / https://doi.org/10.3332/ecancer.2019.977

Conference Report: Towards universal coverage—highlights from the 2nd Uganda Conference on Cancer and Palliative Care, 5–6 September 2019, Kampala, Uganda

Abstract | Full Article | PDF Published: 12 Nov 2019 / https://doi.org/10.3332/ecancer.2019.976

Short Communication: Elimination of cervical cancer: challenges for developing countries

Abstract | Full Article | PDF Published: 12 Nov 2019 / https://doi.org/10.3332/ecancer.2019.975

Review: Barriers to the composition and implementation of advance directives in oncology: a literature review

Abstract | Full Article | PDF Published: 12 Nov 2019 / https://doi.org/10.3332/ecancer.2019.974



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation